BioNeutra Global Corporation
BGA.V
TSX
09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
---|---|---|---|---|---|
Revenue | 1.89M | 2.35M | 2.21M | 1.90M | 2.52M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 1.89M | 2.35M | 2.21M | 1.90M | 2.52M |
Cost of Revenue | 1.22M | 2.06M | 1.93M | 2.26M | 1.88M |
Gross Profit | 665.30K | 290.20K | 286.90K | -355.40K | 638.30K |
SG&A Expenses | 848.10K | 981.70K | 778.30K | 1.03M | 944.90K |
Depreciation & Amortization | 42.30K | 43.20K | 41.00K | 66.00K | 30.30K |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 2.15M | 3.11M | 2.77M | 3.39M | 2.88M |
Operating Income | -261.40K | -763.70K | -556.40K | -1.49M | -362.80K |
Income Before Tax | -995.80K | -922.20K | -683.70K | -891.70K | -943.50K |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -995.80K | -922.20K | -683.70K | -891.70K | -943.50K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -995.80K | -922.20K | -683.70K | -891.70K | -943.50K |
EBIT | -261.40K | -763.70K | -556.40K | -1.49M | -362.80K |
EBITDA | -56.30K | -593.70K | -371.30K | -1.29M | -158.80K |
EPS Basic | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 |
Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
EPS Diluted | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 |
Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Average Basic Shares Outstanding | 46.70M | 46.70M | 46.70M | 46.45M | 46.45M |
Average Diluted Shares Outstanding | 46.70M | 46.70M | 46.70M | 46.45M | 46.45M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |